Exagen Inc (OQ:XGN)

Business Focus: Healthcare Facilities & Services

Mar 18, 2024 08:00 am ET
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52.5 million for the...
Mar 08, 2024 09:00 am ET
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024. John Aballi,...
Mar 07, 2024 04:05 pm ET
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024. John Aballi, Exagen’s President and Chief...
Jan 30, 2024 04:05 pm ET
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird,...
Jan 07, 2024 12:00 pm ET
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance. Select...
Nov 13, 2023 04:05 pm ET
Exagen Inc. Reports Strong Third Quarter 2023 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. Recognized total revenue of $13.4 million for the third quarter of 2023. Delivered gross...
Nov 09, 2023 04:05 pm ET
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. Exagen will focus on the development of novel patented biomarkers...
Nov 02, 2023 04:05 pm ET
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, which takes place November 16th, 2023, at the...
Oct 30, 2023 04:05 pm ET
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November 13, 2023. John Aballi, Exagen’s President and Chief...
Sep 28, 2023 04:05 pm ET
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15,...
Sep 12, 2023 04:05 pm ET
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay...
Aug 07, 2023 08:00 am ET
Exagen Inc. Reports Strong Second Quarter 2023 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. Second Quarter Highlights: Delivered a record 37,749 AVISE® CTD tests in the second quarter,...
Jul 26, 2023 04:05 pm ET
Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 43rd Annual Growth Conference, which takes place August 7-10, 2023, at the InterContinental Boston Hotel in...
Jul 25, 2023 04:05 pm ET
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before the market open on Monday, August 7, 2023. John Aballi, Exagen’s President and Chief Executive...
Jul 24, 2023 04:05 pm ET
Exagen Inc. Appoints Paul Kim to Board of Directors
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial...
May 30, 2023 09:00 am ET
Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43rd Annual Growth Stock Conference, which takes place June 6-8, 2023, in Chicago at the Loews Chicago Hotel. John...
May 15, 2023 04:05 pm ET
Exagen Inc. Reports First Quarter 2023 Results
Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023. First Quarter Highlights: Delivered a record 37,312 AVISE® CTD tests in the first...
May 01, 2023 04:05 pm ET
Exagen Announces Campaign for Lupus Awareness Month
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful...
Apr 24, 2023 04:05 pm ET
Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2023, after the market close on Monday, May 15, 2023. John Aballi, Exagen’s President and Chief Executive...
Mar 20, 2023 04:05 pm ET
Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: Record 135,210 flagship AVISE® CTD tests, for the...
Mar 06, 2023 04:05 pm ET
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2022, after the market close on Monday, March 20, 2023. John Aballi, Exagen’s President and...
Feb 27, 2023 09:00 am ET
Exagen Inc. to Participate in Upcoming March Conferences
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March investor conferences. Cowen 43rd Annual Health Care Conference March 6-8, 2023, at the Boston...
Jan 30, 2023 04:05 pm ET
Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird,...
Jan 23, 2023 09:00 am ET
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk,...
Nov 14, 2022 04:05 pm ET
Exagen Inc. Reports Third Quarter 2022 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights: Total revenue of $14.7 million recognized in the third quarter...
Nov 08, 2022 04:05 pm ET
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth quarter investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health &...
Oct 31, 2022 04:05 pm ET
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022. John Aballi, Exagen’s President and Chief...
Oct 17, 2022 09:00 am ET
Exagen Announces Appointment of John Aballi as CEO
Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.  Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at...
Oct 04, 2022 08:25 am ET
Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the company’s rheumatoid arthritis...
Sep 20, 2022 04:05 pm ET
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2022, being held November 10-14,...
Sep 01, 2022 04:05 pm ET
Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory University has led to a publication in Nature, found here. Exagen’s clinical test offerings, run on...
Aug 04, 2022 04:06 pm ET
Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic test for rheumatoid arthritis using the...
Aug 04, 2022 04:05 pm ET
Exagen Inc. Reports Second Quarter 2022 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights: Recognized total revenue of $9.0 million for the second quarter of...
Jul 25, 2022 04:05 pm ET
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, which takes place August 8-11, 2022, in Boston at the InterContinental Boston...
Jul 21, 2022 04:05 pm ET
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen’s President and Chief Executive...
Jul 05, 2022 08:25 am ET
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing enables decisive clinical action in the differential diagnosis for lupus. The Complement Activation...
Jun 09, 2022 08:25 am ET
Exagen Inc. Expands Coverage with MediNcrease
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC’s national provider network, providing enhanced care to their approximately 7.5 million...
May 26, 2022 04:05 pm ET
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Stock Conference, which takes place June 6-9, 2022, in Chicago at the Loews Chicago Hotel. Ron...
May 16, 2022 04:05 pm ET
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered service with Alivio Health, providing enhanced care to their 150,000 members. The agreement...
May 11, 2022 04:06 pm ET
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has provided pricing for AVISE® Lupus. Noridian’s decision to price AVISE Lupus follows the...
May 11, 2022 04:05 pm ET
Exagen Inc. Reports First Quarter 2022 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2022. First Quarter Highlights: Generated total revenue of $10.4 million for the first quarter of...
May 01, 2022 12:00 pm ET
Exagen Announces Five-Week Campaign for Lupus Awareness Month
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those...
Apr 25, 2022 04:05 pm ET
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen’s President and Chief Executive...
Apr 20, 2022 04:05 pm ET
Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2 Conference, which takes place May 3rd - 4th, 2022, in New York City at the Westin New York Grand...
Mar 30, 2022 08:25 am ET
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members....
Mar 22, 2022 04:06 pm ET
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as an in-network benefit for patients. Effective June 1, 2022, AVISE test offerings become an...
Mar 22, 2022 04:05 pm ET
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights: Record total revenue of $48.3 million for the year...
Mar 16, 2022 04:05 pm ET
Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB) with appointment of seven doctors and rheumatology experts. The SAB includes Stanley Cohen, MD;...
Mar 09, 2022 04:05 pm ET
Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum, which takes place March 22-23, 2022. Ron Rocca, Exagen’s...
Mar 08, 2022 04:05 pm ET
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2021 after the market close on Tuesday, March 22, 2022. Ron Rocca, Exagen’s President and...
Feb 02, 2022 04:05 pm ET
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022. Ron Rocca,...
Jan 09, 2022 12:00 pm ET
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus on...
Nov 17, 2021 04:05 pm ET
Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. From November 22nd to December 2nd, presentations will be available for...
Nov 10, 2021 04:05 pm ET
Exagen Inc. Reports Third Quarter 2021 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021. Third Quarter Highlights: Generated total revenue of $12.3 million for the third quarter of...
Nov 04, 2021 04:05 pm ET
Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum, which takes place November 18th, 2021. Ron...
Oct 27, 2021 04:05 pm ET
Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. Ron Rocca, Exagen’s President and Chief...
Oct 27, 2021 08:25 am ET
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered service with Inland Empire Health Plan (IEHP), providing enhanced care to over 1.4 million...
Oct 25, 2021 08:25 am ET
Exagen Inc. Announces $27.2 Million Debt Refinancing
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital Partners, LLC...
Oct 21, 2021 04:05 pm ET
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) virtual annual meeting, ACR Convergence 2021. The event is...
Sep 13, 2021 04:15 pm ET
Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30th, 2021. Ron Rocca, Exagen’s President...
Aug 09, 2021 04:05 pm ET
Exagen Inc. Reports Second Quarter 2021 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights: Generated record total revenue of $12.8 million for the second quarter...
Jul 30, 2021 08:25 am ET
Exagen Appoints Ana Hooker to Board of Directors
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the addition of Ms. Ana Hooker as an additional independent member to its Board of Directors, effective July 29, 2021. “We are excited to welcome...
Jul 29, 2021 08:25 am ET
Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference, which takes place August 10-12, 2021. Ron Rocca, Exagen’s President and Chief...
Jul 26, 2021 04:05 pm ET
Exagen to Announce Second Quarter 2021 Financial Results on August 9, 2021
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after the market close on Monday, August 9, 2021. Ron Rocca, Exagen’s President and Chief Executive...
Jul 13, 2021 04:05 pm ET
AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in Lupus & Science Medicine, found here: https://lupus.bmj.com/content/8/1/e000528.full. This...
Jun 18, 2021 08:29 am ET
Exagen Elects Frank Stokes to Board of Directors
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company’s stockholders approved the election of Mr. Frank Stokes as an additional independent member to its Board of Directors at the Annual...
May 24, 2021 04:05 pm ET
Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth Stock Conference which takes place June 1-3, 2021. Ron Rocca, Exagen’s President and Chief...
May 11, 2021 04:05 pm ET
Exagen Inc. Reports First Quarter 2021 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2021. First Quarter Highlights: Generated total revenue of $10.6 million for the quarter ended...
May 04, 2021 04:05 pm ET
Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute jointly announced today the execution of a research collaboration agreement and an...
May 03, 2021 08:25 am ET
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely...
Apr 27, 2021 04:05 pm ET
Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021. Ron Rocca, Exagen’s President and Chief Executive...
Mar 29, 2021 08:25 am ET
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of...
Mar 25, 2021 04:15 pm ET
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant...
Mar 22, 2021 10:01 pm ET
Exagen Inc. Announces Pricing of Public Offering of Common Stock
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares to...
Mar 22, 2021 04:05 pm ET
Exagen Inc. Announces Proposed Public Offering of Common Stock
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition,...
Mar 16, 2021 04:05 pm ET
Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights: Generated total revenue of $42.0 million for the year...
Mar 02, 2021 08:00 am ET
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive Officer, and...
Feb 22, 2021 04:05 pm ET
Exagen Inc. to Participate in the Cowen 41st Annual Health Care Conference
Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes place March 1-4, 2021. Ron Rocca, Exagen’s President and Chief Executive Officer, and Kamal...
Feb 03, 2021 04:05 pm ET
Exagen Inc. To Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 17-19, 2021. Ron Rocca, Exagen’s President...
Jan 21, 2021 04:05 pm ET
Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV,...
Jan 10, 2021 06:00 pm ET
Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported preliminary, unaudited financial results for the quarter ended December 31, 2020. Testing...
Jan 05, 2021 04:05 pm ET
Exagen Inc. To Participate in 2021 ICR Conference
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference, which takes place January...
Jan 04, 2021 04:05 pm ET
Exagen Inc. Partners with Oregon’s St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV,...
Nov 18, 2020 04:05 pm ET
Exagen Inc. to Participate in December Investor Conferences
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor conferences:...
Nov 16, 2020 08:25 am ET
Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Nov 10, 2020 04:05 pm ET
Exagen Inc. Reports Third Quarter 2020 Results
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended September 30, 2020. Third Quarter Highlights:...
Nov 09, 2020 08:25 am ET
Exagen Inc. To Participate in November Investor Conferences
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following November investor conferences....
Nov 02, 2020 08:25 am ET
Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. The Brigham is...
Oct 27, 2020 04:05 pm ET
Exagen to Announce Third Quarter Financial Results on November 10, 2020
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended September 30, 2020 after the...
Oct 21, 2020 04:05 pm ET
Exagen Showcases Six Scientific Presentations at ACR’s First Virtual Annual Meeting in November 2020
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR)...
Oct 12, 2020 04:05 pm ET
New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the publication of a study evaluating the economic benefits AVISE® Lupus testing, titled...
Sep 29, 2020 08:25 am ET
Exagen Inc. Announces Agreement with Provider Network of America Expanding Access for AVISE® Tests to 8 Million Members
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases, today announced that it has entered into a preferred provider network agreement with...
Sep 23, 2020 04:10 pm ET
Exagen Appoints Wendy Johnson to Board of Directors
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is proud to announce the addition of Ms. Wendy S. Johnson as an additional independent member to its Board of...
Sep 21, 2020 08:25 am ET
Exagen Launches Test to Aid in the Detection of ANCA-Associated Vasculitis (AAV)
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the launch of AVISE® Vasculitis AAV, a new testing panel of individual analytes designed to...
Sep 03, 2020 04:05 pm ET
Exagen to Participate in 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that its management team will participate in the Cantor Fitzgerald Virtual Global Healthcare...
Aug 03, 2020 04:05 pm ET
Exagen Inc. Announces a Collaboration with Hospital for Special Surgery (HSS) for Antiphospholipid Syndrome
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a collaboration with Hospital for Special Surgery (HSS) in New York City. This well-respected...
Jul 30, 2020 04:25 pm ET
Exagen to Present at the Canaccord Genuity 40th Annual Growth Conference
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that Ron Rocca, President and Chief Executive Officer of Exagen, will present at the Canaccord...
Jul 28, 2020 07:00 am ET
Exagen Inc. Reports Second Quarter 2020 Results
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended June 30, 2020. Second Quarter Highlights:...
Jul 27, 2020 04:05 pm ET
Exagen Inc. AVISE Testing Now Covered and In-Network with TRICARE East
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, MTX and HCQ) will...
Jul 16, 2020 10:45 am ET
Exagen to Announce Second Quarter Financial Results on July 28, 2020
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended June 30, 2020 before the market...
Jun 17, 2020 08:25 am ET
Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration for a Novel, Rule-In, Blood Test to Support the Diagnosis of Fibromyalgia
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced it has entered into an exclusive worldwide license agreement with the Ohio State Innovation...
Jun 03, 2020 08:25 am ET
Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a clinical trial in collaboration with Duke University in Durham, NC. The Duke Lupus Clinic is...
May 26, 2020 08:25 am ET
Exagen to Present at the William Blair 40th Annual Growth Stock Conference
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that Ron Rocca, President and Chief Executive Officer of Exagen, will present at the William...
May 11, 2020 04:05 pm ET
Exagen Inc. Reports First Quarter 2020 Results
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended March 31, 2020. First Quarter Highlights:...
Apr 27, 2020 08:25 am ET
Exagen to Announce First Quarter Financial Results on May 11, 2020
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Mar 25, 2020 04:05 pm ET
Exagen Inc. Reports Fourth Quarter and Full Year 2019 Results
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Mar 24, 2020 08:25 am ET
Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (CMO), and Anja...
Mar 16, 2020 08:19 am ET
Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Mar 11, 2020 08:25 am ET
Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Mar 09, 2020 08:20 am ET
Exagen Inc. Partners with Three California Medical Groups to Offer AVISE Testing as Covered In-Network Benefit for Their Patients
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Feb 18, 2020 08:25 am ET
Exagen to Present at Cowen and Company 40th Annual Healthcare Conference
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Jan 30, 2020 06:55 am ET
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership
Interpace Biosciences , Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Ron Rocca, President & CEO of Exagen, Inc. (NASDAQ: XGN) has been appointed to the Interpace Board of Directors....
Dec 16, 2019 08:25 am ET
Exagen Announces Addition to Russell 3000® and 2000® Indexes
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Dec 10, 2019 08:10 am ET
National Experts in Autoimmunity Tapped to Serve on Exagen’s Scientific Advisory Board
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Nov 22, 2019 08:25 am ET
Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Nov 21, 2019 08:25 am ET
Exagen Inc. Announces $26.2 Million Debt Refinancing
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Nov 20, 2019 05:15 am ET
Exagen Inc. to Participate in the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Nov 12, 2019 04:05 pm ET
Exagen Inc. Reports Third Quarter 2019 Results
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Nov 07, 2019 08:14 am ET
Exagen to Participate in Canaccord Genuity 13th Annual MedTech & Diagnostics Forum on November 21, 2019
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Oct 29, 2019 08:00 am ET
Exagen to Announce Third Quarter 2019 Financial Results on November 12th, 2019
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Oct 28, 2019 08:15 am ET
Exagen Featured in Nine Scientific Presentations at 2019 ACR/ARHP Annual Meeting in Atlanta
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Oct 24, 2019 08:20 am ET
AVISE® MTX Test from Exagen Supports Horizon Therapeutics plc Clinical Trial to Evaluate Pegloticase with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
Exagen Inc. (Nasdaq: XGN), is pleased to announce clinical study support for Horizon Therapeutics plc (Nasdaq: HZNP) to measure methotrexate polyglutamates (MTXPGs), the active metabolites of methotrexate (MTX) in the MIRROR Randomized Controlled...
Oct 21, 2019 08:15 am ET
Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Oct 15, 2019 08:15 am ET
Exagen Announces Publication of Two Key Studies Validating Clinical Performance of AVISE® Lupus in Patients with Probable SLE and Demonstrating Superior Clinical Utility Compared to Standard Diagnosti
Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...
Sep 23, 2019 01:36 pm ET
Exagen Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.